Related Experiment Videos
Cytomegalovirus therapy: current constraints and future opportunities
1Department of Virology, Royal Free and University College Medical School, London, UK. p.griffiths@rfc.ucl.ac.uk
Current Opinion in Infectious Diseases
|April 20, 2002
Summary
Recent findings reveal cytomegalovirus (CMV) rapidly replicates and develops ganciclovir resistance. This virus contributes to transplant rejection and atherosclerosis, necessitating new, cost-effective treatments.
Area of Science:
- Virology
- Immunology
- Transplant Medicine
Background:
- Cytomegalovirus (CMV) is increasingly recognized for its significant impact beyond end-organ disease.
- Recent research highlights CMV's role in complex post-transplant complications.
Purpose of the Study:
- To summarize recent advancements in understanding cytomegalovirus.
- To underscore the need for novel therapeutic strategies against CMV.
Main Methods:
- Review of recent scientific literature on cytomegalovirus.
- Analysis of CMV's clinical impact and treatment resistance patterns.
Main Results:
- Cytomegalovirus is identified as a rapidly replicating virus.
- Frequent development of ganciclovir resistance during chronic treatment is observed.
- CMV is implicated in renal transplant rejection and accelerated atherosclerosis post-heart transplant.
Conclusions:
- Current understanding of cytomegalovirus has significantly evolved.
- There is an urgent need for new, safe, potent, and cost-effective CMV treatments.